143 related articles for article (PubMed ID: 20149360)
41. A lower ongoing pregnancy rate can be expected when GnRH agonist is used for triggering final oocyte maturation instead of HCG in patients undergoing IVF with GnRH antagonists.
Kolibianakis EM; Schultze-Mosgau A; Schroer A; van Steirteghem A; Devroey P; Diedrich K; Griesinger G
Hum Reprod; 2005 Oct; 20(10):2887-92. PubMed ID: 15979994
[TBL] [Abstract][Full Text] [Related]
42. A comparison of gonadotropin-releasing hormone (GnRH) antagonist and GnRH agonist flare protocols for poor responders undergoing in vitro fertilization.
Berin I; Stein DE; Keltz MD
Fertil Steril; 2010 Feb; 93(2):360-3. PubMed ID: 19131055
[TBL] [Abstract][Full Text] [Related]
43. A comparison of live birth rates and cumulative ongoing pregnancy rates between Europe and North America after ovarian stimulation with corifollitropin alfa or recombinant follicle-stimulating hormone.
Boostanfar R; Mannaerts B; Pang S; Fernandez-Sanchez M; Witjes H; Devroey P;
Fertil Steril; 2012 Jun; 97(6):1351-8. PubMed ID: 22459628
[TBL] [Abstract][Full Text] [Related]
44. [Corifollitropin alfa compared to daily FSH in controlled ovarian stimulation for oocyte donors].
Benchabane M; Santulli P; Maignien C; Bourdon M; De Ziegler D; Chapron C; Gayet V
Gynecol Obstet Fertil Senol; 2017 Feb; 45(2):83-88. PubMed ID: 28368800
[TBL] [Abstract][Full Text] [Related]
45. Ovarian response markers lead to appropriate and effective use of corifollitropin alpha in assisted reproduction.
La Marca A; D'Ippolito G
Reprod Biomed Online; 2014 Feb; 28(2):183-90. PubMed ID: 24368127
[TBL] [Abstract][Full Text] [Related]
46. Short coasting of 1 or 2 days by withholding both gonadotropins and gonadotropin-releasing hormone agonist prevents ovarian hyperstimulation syndrome without compromising the outcome.
Moon HS; Joo BS; Moon SE; Lee SK; Kim KS; Koo JS
Fertil Steril; 2008 Dec; 90(6):2172-8. PubMed ID: 18439601
[TBL] [Abstract][Full Text] [Related]
47. Antral follicle count is a significant predictor of livebirth in in vitro fertilization cycles.
Maseelall PB; Hernandez-Rey AE; Oh C; Maagdenberg T; McCulloh DH; McGovern PG
Fertil Steril; 2009 Apr; 91(4 Suppl):1595-7. PubMed ID: 19100533
[TBL] [Abstract][Full Text] [Related]
48. Can 200 IU of hCG replace recombinant FSH in the late follicular phase in a GnRH-antagonist cycle? A pilot study.
Blockeel C; De Vos M; Verpoest W; Stoop D; Haentjens P; Devroey P
Hum Reprod; 2009 Nov; 24(11):2910-6. PubMed ID: 19617207
[TBL] [Abstract][Full Text] [Related]
49. Gonadotropin-releasing hormone (GnRH) antagonist plus recombinant luteinizing hormone vs. a standard GnRH agonist short protocol in patients at risk for poor ovarian response.
De Placido G; Mollo A; Clarizia R; Strina I; Conforti S; Alviggi C
Fertil Steril; 2006 Jan; 85(1):247-50. PubMed ID: 16412769
[TBL] [Abstract][Full Text] [Related]
50. A randomised controlled trial of 300 versus 225 IU recombinant FSH for ovarian stimulation in predicted normal responders by antral follicle count.
Jayaprakasan K; Hopkisson J; Campbell B; Johnson I; Thornton J; Raine-Fenning N
BJOG; 2010 Jun; 117(7):853-62. PubMed ID: 20353458
[TBL] [Abstract][Full Text] [Related]
51. Retrieval of zona-free immature oocytes in a woman with recurrent empty follicle syndrome: a case report.
Duru NK; Cincik M; Dede M; Hasimi A; Baser I
J Reprod Med; 2007 Sep; 52(9):858-63. PubMed ID: 17939607
[TBL] [Abstract][Full Text] [Related]
52. A randomized controlled trial of increasing recombinant follicle-stimulating hormone after initiating a gonadotropin-releasing hormone antagonist for in vitro fertilization-embryo transfer.
Propst AM; Bates GW; Robinson RD; Arthur NJ; Martin JE; Neal GS
Fertil Steril; 2006 Jul; 86(1):58-63. PubMed ID: 16753156
[TBL] [Abstract][Full Text] [Related]
53. Follicular growth and oocyte maturation in GnRH agonist and antagonist protocols for in vitro fertilisation and embryo transfer.
Depalo R; Lorusso F; Palmisano M; Bassi E; Totaro I; Vacca M; Trerotoli P; Masciandaro P; Selvaggi L
Gynecol Endocrinol; 2009 May; 25(5):328-34. PubMed ID: 19340626
[TBL] [Abstract][Full Text] [Related]
54. Efficacy of recombinant human follicle-stimulating hormone in improving oocyte quality in assisted reproductive techniques.
Cheon KW; Byun HK; Yang KM; Song IO; Choi KH; Yoo KJ
J Reprod Med; 2004 Sep; 49(9):733-8. PubMed ID: 15493565
[TBL] [Abstract][Full Text] [Related]
55. Gonadotropin-releasing hormone antagonist and metformin for treatment of polycystic ovary syndrome patients undergoing in vitro fertilization-embryo transfer.
Doldi N; Persico P; Di Sebastiano F; Marsiglio E; Ferrari A
Gynecol Endocrinol; 2006 May; 22(5):235-8. PubMed ID: 16785142
[TBL] [Abstract][Full Text] [Related]
56. Pregnancy outcome following in vitro fertilization-embryo transfer (IVF-ET) in women aged < 37, undergoing ovulation induction with human FSH compared with recombinant FSH: a randomised controlled study.
Gholami H; Vicari E; Molis M; La Vignera S; Papaleo E; Cappiello F
Eur Rev Med Pharmacol Sci; 2010 Feb; 14(2):97-102. PubMed ID: 20329567
[TBL] [Abstract][Full Text] [Related]
57. GnRH antagonists in ovarian stimulation for IVF.
Tarlatzis BC; Fauser BC; Kolibianakis EM; Diedrich K; Rombauts L; Devroey P
Hum Reprod Update; 2006; 12(4):333-40. PubMed ID: 16567347
[TBL] [Abstract][Full Text] [Related]
58. Elective cryopreservation of all pronuclear oocytes after GnRH agonist triggering of final oocyte maturation in patients at risk of developing OHSS: a prospective, observational proof-of-concept study.
Griesinger G; von Otte S; Schroer A; Ludwig AK; Diedrich K; Al-Hasani S; Schultze-Mosgau A
Hum Reprod; 2007 May; 22(5):1348-52. PubMed ID: 17303632
[TBL] [Abstract][Full Text] [Related]
59. [Clinical application of gonadotropin-releasing hormone antagonist in Chinese women undergoing controlled ovarian hyperstimulation for in vitro fertilization and embryo transfer].
Chen SL; Yin MN; Sun L; Li H; Chen X; Song HD; He JX; Zhu L; Xing FQ
Nan Fang Yi Ke Da Xue Xue Bao; 2007 May; 27(5):588-90. PubMed ID: 17545062
[TBL] [Abstract][Full Text] [Related]
60. Short follicular phase of stimulation following corifollitropin alfa or daily recombinant FSH treatment does not compromise clinical outcome: a retrospective analysis of the Engage trial.
Mardešič T; Mannaerts B; Abuzeid M; Levy M; Witjes H; Fauser BC;
Reprod Biomed Online; 2014 Apr; 28(4):462-8. PubMed ID: 24581989
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
